Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Muvalaplin in Adults With Elevated Lipoprotein(a) and Cardiovascular Risk
NCT07157774Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2025
- Primary completion
- Mar 2031
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of muvalaplin in atherosclerotic cardiovascular disease (ASCVD), elevated lipoprotein(a) (Lp(a)), sponsored by Eli Lilly and Company. Started Sep 2025; status: recruiting.
02
Drugs
muvalaplin
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT07157774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07157774.